Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
This observational study is looking for ways to find pancreatic cancer earlier, as it often has a poor prognosis. Researchers are trying to identify biomarkers (biological signs) in duodenal fluid (fluid from the first part of your small intestine) that could help with early diagnosis. This fluid can be collected during routine procedures like endoscopy. The study aims to compare these biomarkers in people with and without pancreatic cancer. You may be able to join if you are at least 19 years old and are already scheduled for an upper endoscopy, endoscopic ultrasound, or ERCP (endoscopic retrograde cholangiopancreatography) for medical reasons. The main goal is to find these biomarkers within one year from when you start the study.
- Study design
- This is an observational study planning to enroll 263 participants. It is not a treatment study, but rather aims to identify biomarkers.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to one year from the start of the study to identify biomarkers.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
At a glance
Conditions
Where it's being run
3 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Identification of Biomarkers for Early Pancreatic Cancer DetectionUp to 1 year from baseline
Area Under the Receiver Operating Characteristic Curve (AUC) and 95% Confidence Interval (CI) of candidate biomarkers in the training cohort. If the AUC falls within ±5% of the target value (0.94), the optimal cutoff value for pancreatic cancer differentiation will be reported using Youden's Index.